<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00572494</url>
  </required_header>
  <id_info>
    <org_study_id>BIOTRONIK Reference 27-1</org_study_id>
    <secondary_id>Not available</secondary_id>
    <nct_id>NCT00572494</nct_id>
  </id_info>
  <brief_title>AMS INSIGHT 1 Study - Bioabsorbable Metal Stent Investigation in Chronic Limb Ischemia Treatment</brief_title>
  <acronym>AMS-INSIGHT1</acronym>
  <official_title>Bioabsorbable Metal Stent Investigation in Chronic Limb Ischemia Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Flanders Medical Research Program</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biotronik SE &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Flanders Medical Research Program</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multicenter, randomized clinical trial, Follow-up at 1-, 6- and 12 months

      This clinical investigation is first of all designed to demonstrate the safety and
      effectiveness of the MAGIC EXPLORER stent system. The primary objectives of the study are to
      evaluate the safety and 6-month patency of the bioabsorbable MAGIC EXPLORER stent in patients
      with stenotic or occlusive atherosclerotic disease of the infrapopliteal arteries. Secondary
      endpoints are the procedural success, patency at all follow-ups, late lumen loss and
      limb-salvage rate. Peri-procedural complications (within 24 hours) will be evaluated.
      Furthermore, data of the balloon catheter PLEON EXPLORER will be collected to demonstrate its
      effectiveness and safety.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy : patency of the AMS, defined as the absence of a hemodynamically significant restenosis (&gt; 50%)</measure>
    <time_frame>6 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Complications at 1 month post-procedure (major amputations or any cause of death)</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immediate angiographic procedural success, defined as maximal 30% residual stenosis on visual assessment of the planned treatment area.</measure>
    <time_frame>procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patency at follow-up visits determined with Color Flow Doppler Ultrasound (CFDU)</measure>
    <time_frame>1 &amp; 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late lumen loss at 6 months.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Limb-salvage rate at follow-up visits, defined as lack of major amputation.</measure>
    <time_frame>1 &amp; 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">117</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stenting with AMS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PTA alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MAGIC EXPLORER (Biotronik AG)</intervention_name>
    <description>The lesion is pre-dilated with the PLEON EXPLORER balloon with a length of 10 mm or 15 mm or 20 mm under angiographic control. After dilation, the stenosed area is treated by one AMS implant. If the implanted stent is not fully apposed to the vessel wall or if initial angiography reveals a residual stenosis, the stent may be post-dilated with the delivery system balloon. If necessary, a high-pressure, non-compliant balloon catheter may be used.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PLEON EXPLORER (Biotronik AG)</intervention_name>
    <description>The lesion is dilated with the PLEON EXPLORER balloon with lengths of 10 mm or 15 mm or 20 mm, respectively. In case that the PTA procedure results in a residual stenosis of &gt;50%, the AMS implant should be used to improve the result. A flow-limiting dissection does not qualify for stenting. Best effort must be made to obtain a satisfactory result (e.g. multiple and prolonged inflations) before a patient in the PTA group can be treated with a stent.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stenotic (&gt; 50%) or occlusive atherosclerotic disease of the infrapopliteal arteries

          -  Length of lesion &lt; 20mm (less than one stent length)

          -  Reference vessel diameter should be 3.0-3.5 mm

          -  A maximum of two lesions in one infrapopliteal vessel treated within the study, or in
             two vessels of two different legs. (PTA treatment of other infrapopliteal lesions in
             non-study vessels is allowed outside the study).

          -  Symptomatic critical limb ischemia (Rutherford 4, 5)

          -  The patient must be ≥ 50 years.

          -  Life-expectancy of more than 6 months

          -  The subject or legal guardian has been informed of the nature of the study; agrees to
             its provisions and has signed informed consent

          -  The patient must be available for the appropriate follow-up times for the duration of
             the study

          -  The patient is capable to follow all study requirements.

        Exclusion Criteria:

          -  Patient refusing treatment

          -  The reference segment diameter is not suitable for available stent design

          -  Length of lesion requires more than one stent implantation

          -  Previously implanted stent(s) or PTA at the same lesion site

          -  Lesion lies within or adjacent to an aneurysm

          -  Inflow-limiting arterial lesions left untreated

          -  The patient has a known allergy to heparin, Aspirin or other
             anticoagulant/antiplatelet therapies or a bleeding diatheses or is unable, or
             unwilling, to tolerate such therapies.

          -  The patient takes Phenprocoumon (Marcumar).

          -  The patient has a history of prior life-threatening contrast media reaction.

          -  The patient is currently enrolled in another investigational device or drug trial.

          -  The patient is currently breast-feeding, pregnant or intends to become pregnant.

          -  The patient is mentally ill or retarded.

          -  The patient is liable for military or civilian service.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Bosiers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AZ Sint-Blasius, Dendermonde, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Evelyn Diessel, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Biotronik SE &amp; Co. KG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Universität Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.ö. Landeskrankenhaus Klagenfurt</name>
      <address>
        <city>Klagenfurt</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgem. Krankenhaus Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imelda Ziekenhuis Bonheiden</name>
      <address>
        <city>Bonheiden</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ St-Blasius</name>
      <address>
        <city>Dendermonde</city>
        <zip>9200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Humaine Kliniken Bad Saarow</name>
      <address>
        <city>Bad Saarow</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ev. Krankenhaus Herberge Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint-Elisabeth Ziekenhuis Tilburg</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2007</study_first_submitted>
  <study_first_submitted_qc>December 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2007</study_first_posted>
  <last_update_submitted>February 7, 2008</last_update_submitted>
  <last_update_submitted_qc>February 7, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2008</last_update_posted>
  <responsible_party>
    <name_title>Marc Bosiers, MD</name_title>
    <organization>AZ Sint-Blasius hospital, Dendermonde, Belgium</organization>
  </responsible_party>
  <keyword>Tibial arteries</keyword>
  <keyword>Absorbable implants</keyword>
  <keyword>Stents</keyword>
  <keyword>Limb salvage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

